Document Top

  • Avastin is well tolerated when combined with platinum‐doublet chemotherapy

    E4599: 14.2 months OS in adenocarcinoma

     

     

     More

  • SAiL: Avastin can be safely combined with a range of chemotherapy regimens

    AVAiL: PFS benefit with Avastin

     

     

     More

  • AVAiL: Avastin‐based therapy provides efficacy across patient populations

    SAiL: OS of 14.6 months

     

     

     More

  • VEGF and malignant pleural effusion in lung cancer

    SAiL: proven efficacy and safety benefits with Avastin

     

     

     More

 
Case studies

Patient cases

Physicians share their experience and discuss  treatment options for patients with NSCLC.
The case presentations are designed to provide an insight into clinical practice and treatment decisions supported by trial data.

More

LATEST PATIENT CASES

Educational webcasts

Educational webcasts

A series of webcasts highlighting some of the key learning points from scientific and clinical data.
Experienced physicians and scientists share their thoughts on the development of anticancer agents and discuss the options available for the treatment of NSCLC.

More

LATEST WEBCASTS

  • Expert perspectives in NSCLC

    Expert perspectives in NSCLC

    Avastin in a lung cancer patient (Prof Jürgen Wolf)

    View

  • The SAiL experience SAiL investigator

    The SAiL experience SAiL investigator

    Professor Lucio Crino discusses the clinical relevance of newly reported data for Avastin in NSCLC.

    View

  • Controlling angiogenesis to control tumour growth

    Controlling angiogenesis to control tumour growth

    Avastin precisely targets VEGF to inhibit angiogenesis for continuous tumour control

    View

Watch more

  • Maximising survival in NSCLC

    Maximising survival in NSCLC

    Anti-angiogenic therapy in NSCLC: real-life perspectives (Prof Jürgen Wolf)

    View

  • Anti-VEGF therapy: innovating NSCLC treatment

    Anti-VEGF therapy: innovating NSCLC treatment

    An overview of Avastin clinical data (Prof Román Pérez-Soler)

    View

  • Anti-VEGF therapy for NSCLC

    Anti-VEGF therapy for NSCLC

    The importance of anti-VEGF therapy for continued tumour control (Dr Ulrich Gatzemeier)

    View

Watch more

  • NSCLC patient case

    NSCLC patient case

    A patient with centrally located adenocarcinoma of the lung (Dr Martin Reck)

    View

  • NSCLC patient case

    NSCLC patient case

    A patient with adenocarcinoma of the lung and pre-existing hypertension (Dr Monika Serke)

    View

  • NSCLC patient case

    NSCLC patient case

    A patient who contacted her GP after experiencing pain in her lower right arm (Dr Martin Reck)

    View

Watch more

Upcoming Conferences

  • USA
    AACR
    ,
    Chicago, IL, USA
    31 March 2012 - 04 April 2012
  • Spain
    EONS
    ,
    Valencia, Spain
    26-27 April 2012
  • Spain
    EACR
    ,
    Barcelona, Spain
    7-10 July 2012

More upcoming conferences

x

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.

OK Cancel